Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells

Leukemia

Volumn 29, Issue 7, 2015, Pages 1605-1608

  Pardanani, A ^a   Lasho, T ^a   Chen, D ^b   Kimlinger, T K ^a   Finke, C ^a   Zblewski, D ^a   Patnaik, M M ^a   Reichard, K K ^b   Rowinsky, E ^c   Hanson, C A ^b   Brooks, C ^c   Tefferi, A ^a  

^a Division of Hematology   (United States)

^b MAYO CLINIC   (United States)

^c Stemline Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM CHLORIDE; CD123 ANTIGEN; PEROXIDASE; IL3RA PROTEIN, HUMAN;

ANTIGEN EXPRESSION; ENDOTHELIUM CELL; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LETTER; MAST CELL; NEOPLASTIC MAST CELL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; ROOM TEMPERATURE; STAINING; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION; BONE MARROW; ENZYME IMMUNOASSAY; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE;

BONE MARROW; FLOW CYTOMETRY; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPHENOTYPING; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; MAST CELLS; MASTOCYTOSIS, SYSTEMIC; TUMOR CELLS, CULTURED;

EID: 84937023038     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.16     Document Type: Letter

References (15)

1. Woodcock JM, Bagley CJ, Zacharakis B, Lopez AF. A single tyrosine residue in the membrane-proximal domain of the granulocyte-macrophage colony-stimulating factor, interleukin (IL)-3, and IL-5 receptor common beta-chain is necessary and sufficient for high affinity binding and signaling by all three ligands. J Biol Chem. 1996; 271: 25999-26006
2. Metcalf D, Begley CG, Johnson GR, Nicola NA, Lopez AF, Williamson DJ. Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood. 1986; 68: 46-57
3. Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014; 2: 4
4. Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14: 1777-1784
5. Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, et al. Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk Lymphoma. 2006; 47: 207-222
6. Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, et al. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. Br J Haematol. 2014; 166: 862-874
7. He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, et al. A phase 1 study of the safety, pharmacokinetics, and anti-leukemic activity of the anti-CD123 monoclonal antibody, CSL360, in relapsed, refractory or high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2014; e-pub ahead of print 20 November. 2014; doi:10.3109/10428194.2014.956316
8. Frankel AE, Konopleva M, Hogge D, Rizzieri D, Brooks C, Cirrito T, et al. Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies. J Clin Oncol. 2013; 31: 15
9. Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014; 124: 385-392
10. Valent P, Besemer J, Sillaber C, Butterfield JH, Eher R, Majdic O, et al. Failure to detect IL-3-binding sites on human mast cells. J Immunol. 1990; 145: 3432-3437
11. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Sanchez-Munoz L, Alvarez-Twose I, Nunez R, et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol. 2010; 125: 719-726
12. Moonim MT, Kossier T, van Der Walt J, Wilkins B, Harrison CN, Radia DH. CD30/CD123 expression in systemic mastocytosis does not correlate with aggressive disease. Blood. 2012; 120: 21
13. Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L, et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. (eds) WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research and Cancer (IARC): Lyon, 2008; pp 54-63
14. Pardanani A. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013; 88: 612-624
15. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, et al. Durable responses and improved quality of life with midostaurin (PKC412) in advanced systemic mastocytosis (SM): updated stage 1 results of the Global D2201 trial. Blood. 2013; 122: 21